Dedicated breast positron emission tomography scanners (dbPET) have been developed to make possible higher spatial resolution and sensitivity. The purpose of this study was to investigate the diagnostic performance of a dbPET scanner with an O-shaped detector in patients with known breast cancer.
A total of 82 female patients diagnosed with breast cancer consented to participate in this study (84 lesions: 10 ductal carcinomas in situ (DCIS), 74 invasive cancers). All patients underwent a WB-PET/MRI using Biograph mMR® (Siemens Healthcare) approximately 80 minutes after fluorine-18 fluorodeoxyglucose ((18)F-FDG;3.0MBq/kg) injection, followed by dbPET using Dedicated Breast PET System Elmammo®(Shimadzu, Kyoto, Japan) which required 5 minutes per breast.
The overall imaging sensitivities of dbPET and WB-PET/MRI were 89% (75/84) and 87% (74/84) respectively. The sensitivities excluding 5 lesions which were outside the field of view of dbPET, were 95% (75/79) and 87% (69/79) respectively. The standardized uptake values (SUV) of dbPET (SUVmax mean13, range 1.64-41.6) and WB-PET/MRI (SUVmax mean 5.71, range 1.15-13.3) showed correlation with nuclear grade (NG) (Spearman's rank-correlation coefficient r = 0.507, 0.455, p
Both dbPET and WB-PET/MRI showed high imaging sensitivity, but dbPET had significantly higher sensitivity to high grade DCIS and invasive lesions up to 1cm. This level of diagnostic performance could help to detect early stage cancers as part of breast screening.
Clinical trial identification
We have registerd this trial at UMIN (Univresity Hospital Medical Information network) -CTR Serch Clinical Trials This trial protocol number of UMIN; UMIN000027227 (https://upload.umin.ac.jp/cgi-open-bin/ctr_e/index.cgi) Release date; 02.May.2017
Legal entity responsible for the study
All authors have declared no conflicts of interest.